Research use
For laboratory applications
Worldwide delivery
Controlled-temperature shipping
Technical information
Detailed specifications included
Spike S1 (B.1.1.7, Alpha Variant), Avi-His-Tag (SARS-CoV-2)
Catalog:0421-101001-2
Available sizes
1 optionAvailability
Stock products usually ship within 24–48 hours. Non-stock products may require approximately 2–6 weeks.
Shipping conditions
This product requires dry-ice or controlled-temperature shipping.
Hazardous classification
This product is not currently marked as hazardous.
Recombinant SARS-CoV-2 Spike protein S1 subunit, encompassing amino acids 16-685. This protein corresponds to SARS-CoV-2 Variant B.1.1.7, also known as variant Alpha, originally identified in the United Kingdom. It contains mutations N501Y, A570D, D614G, P681H, and deletions 69-70HV and 144Y. The construct also contains a C-terminal Avi-Tag™ followed by a C-terminal His-tag (6xHis) . The recombinant protein was affinity purified.
This product is intended for laboratory and research use only. Review the supplied documentation before use.
Product Name
Spike S1 (B.1.1.7, Alpha Variant), Avi-His-Tag (SARS-CoV-2)
Catalog Number
0421-101001-2
Available Sizes
1 mg
Hazardous
No
Dry Ice
Yes
Background
The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) . As a first step of the viral replication strategy, the virus attaches to the host cell surface before entering the cell. The Receptor Binding Domain (RBD) of Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. It has been widely suggested that active as well as passive immunizations targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 offer promising protection against viral infection. However recent reports showed that a mutant strain first identified in the UK (B.1.1.7) exhibits higher transmissibility and infectivity. Investigations on the effects of mutations on viral replication and pathogenesis will be critical for developing effective strategies for vaccines and antibody therapies against COVID-19.
Calculated Molecular Weight
78 kDa + glycans
Format
Aqueous buffer solution.
Formulation
8 mM phosphate pH 7.4,110 mM NaCl, 2.2 mM KCl, 20% glycerol
Glycosylation
This protein runs at higher MW by SDS-PAGE due to glycosylation.
Purity
≥ 90%
Shipping Conditions
-80°C
Storage Conditions
At least 6 months at -80°C.
Tag
C-terminal Avi-His-Tag